Published in Eur Radiol on March 06, 2007
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Correlation of ADC value with pathologic indexes in colorectal tumor homografts in Balb/c mouse. Chin J Cancer Res (2014) 0.85
Functional and molecular image guidance in radiotherapy treatment planning optimization. Semin Radiat Oncol (2011) 0.85
Imaging biomarkers: from research to patient care--a shift in view. Eur J Nucl Med Mol Imaging (2007) 0.77
Evaluation of metabolomic changes as a biomarker of chondrogenic differentiation in 3D-cultured human mesenchymal stem cells using proton (1H) nuclear magnetic resonance spectroscopy. PLoS One (2013) 0.75
Early changes in the apparent diffusion coefficient and MMP-9 expression of a cervical carcinoma U14 allograft model following irradiation. Oncol Lett (2017) 0.75
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol (2001) 11.41
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 10.91
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med (2001) 4.30
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer (2006) 3.06
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer (2003) 2.97
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res (1997) 2.96
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol (2005) 2.81
Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem (2001) 2.74
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging (2002) 2.55
In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A (1998) 2.39
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke (1999) 2.25
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol (2006) 2.12
In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res (2000) 2.12
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Near-infrared optical imaging of protease activity for tumor detection. Radiology (1999) 1.97
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
PET imaging of prostate cancer using carbon-11-choline. J Nucl Med (1998) 1.92
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology (1999) 1.86
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol (2001) 1.85
In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng (2005) 1.78
Imaging oxygenation of human tumours. Eur Radiol (2006) 1.78
Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A (1999) 1.73
Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology (2005) 1.73
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol (2003) 1.65
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res (2004) 1.58
Peptide receptor imaging and therapy. J Nucl Med (2000) 1.54
Breast cancer: PET imaging of estrogen receptors. Radiology (1988) 1.53
Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target (1998) 1.53
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res (1996) 1.35
The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res (1959) 1.35
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med (1995) 1.34
Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx (2004) 1.23
Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer (2003) 1.23
Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia (2003) 1.18
Systematic review of diffusion and perfusion imaging in acute ischemic stroke. Stroke (2000) 1.18
PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med (1997) 1.17
Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med (2004) 1.17
Dynamic changes in water ADC, energy metabolism, extracellular space volume, and tortuosity in neonatal rat brain during global ischemia. Magn Reson Med (1996) 1.16
Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol (2001) 1.15
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2002) 1.14
Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci (2002) 1.14
FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol (2005) 1.09
Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med (1984) 1.08
Ischemic stroke: effects of etiology and patient age on the time course of the core apparent diffusion coefficient. Radiology (2001) 1.06
Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging (2002) 1.03
3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med (2003) 0.98
Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des (2004) 0.95
Pathophysiology of the ischemic penumbra--revision of a concept. Cell Mol Neurobiol (1998) 0.90
The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res (1997) 0.90
In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed (1999) 0.89
Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol (1996) 0.88
The use of MRI as an outcome measure in clinical trials. Adv Neurol (2006) 0.87
Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration (1996) 0.85
Magnetic resonance imaging of Alzheimer's disease. Eur Radiol (2006) 0.84
Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology (2005) 0.84
Cytoprotection does not preserve brain functionality in rats during the acute post-stroke phase despite evidence of non-infarction provided by MRI. NMR Biomed (2000) 0.83
18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids (2002) 0.80
The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med (2006) 0.80
Steroid hormone receptors in human breast cancer. Adv Cancer Res (1983) 0.79
The role of labeled Annexin A5 in imaging of programmed cell death. From animal to clinical imaging. Q J Nucl Med (2003) 0.79
Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord (1997) 0.79
HSP-90 inhibitors promise to complement cancer therapies. Nat Biotechnol (2006) 0.79
Recovery of function in cytoprotected cerebral cortex in rat stroke model assessed by functional MRI. Magn Reson Med (2002) 0.78
Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. Nucl Med Biol (1999) 0.78
Thrombolysis 2004: the good, the bad, and the ugly. Rev Neurol Dis (2004) 0.77
A study paradigm allowing comparison of multiple high-resolution rCBV-maps for the examination of drug effects. NMR Biomed (2005) 0.76
Imaging biomarkers predictive of disease/therapy outcome: ischemic stroke and drug development. Prog Drug Res (2005) 0.75
Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers. J Neurooncol (1992) 0.75